|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:abiraterone_acetate
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L02BX03
|
|
gptkbp:CASNumber
|
154229-18-2
|
|
gptkbp:chemicalFormula
|
C26H33NO2
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:drugClass
|
antineoplastic agent
antiandrogen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zytiga
|
|
gptkbp:indication
|
metastatic castration-resistant prostate cancer
metastatic high-risk castration-sensitive prostate cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Biotech
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
CYP17 inhibitor
|
|
gptkbp:patent
|
gptkb:Janssen_Biotech
|
|
gptkbp:pregnancyCategory
|
X (contraindicated in pregnancy)
|
|
gptkbp:prescriptionForm
|
gptkb:tablet
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
hypertension
hypokalemia
liver function abnormalities
|
|
gptkbp:takenWith
|
gptkb:prednisone
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:abiraterone
|
|
gptkbp:bfsLayer
|
6
|